ZA200303771B - Improved treatment. - Google Patents
Improved treatment. Download PDFInfo
- Publication number
- ZA200303771B ZA200303771B ZA200303771A ZA200303771A ZA200303771B ZA 200303771 B ZA200303771 B ZA 200303771B ZA 200303771 A ZA200303771 A ZA 200303771A ZA 200303771 A ZA200303771 A ZA 200303771A ZA 200303771 B ZA200303771 B ZA 200303771B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination
- iop
- prostaglandin
- derivative
- use according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 44
- 150000003180 prostaglandins Chemical class 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 28
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 26
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 26
- 229960004605 timolol Drugs 0.000 claims description 26
- 229960001160 latanoprost Drugs 0.000 claims description 25
- 208000010412 Glaucoma Diseases 0.000 claims description 21
- 210000001742 aqueous humor Anatomy 0.000 claims description 20
- 230000001603 reducing effect Effects 0.000 claims description 17
- 239000002876 beta blocker Substances 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 15
- 210000005036 nerve Anatomy 0.000 claims description 13
- 210000003128 head Anatomy 0.000 claims description 12
- 230000000007 visual effect Effects 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical group CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
- 229960002368 travoprost Drugs 0.000 claims description 6
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 6
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 6
- 229960002704 metipranolol Drugs 0.000 claims description 5
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 claims description 5
- 206010030043 Ocular hypertension Diseases 0.000 claims description 4
- 206010047555 Visual field defect Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 4
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 3
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002122 acebutolol Drugs 0.000 claims description 3
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002213 alprenolol Drugs 0.000 claims description 3
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960002274 atenolol Drugs 0.000 claims description 3
- 229960004324 betaxolol Drugs 0.000 claims description 3
- 229960002781 bisoprolol Drugs 0.000 claims description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 3
- 229960001222 carteolol Drugs 0.000 claims description 3
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 3
- 229960002320 celiprolol Drugs 0.000 claims description 3
- 229960003745 esmolol Drugs 0.000 claims description 3
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 229960001632 labetalol Drugs 0.000 claims description 3
- 229960000831 levobunolol Drugs 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960004255 nadolol Drugs 0.000 claims description 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 3
- 229960004570 oxprenolol Drugs 0.000 claims description 3
- 229960002035 penbutolol Drugs 0.000 claims description 3
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims description 3
- 229960002508 pindolol Drugs 0.000 claims description 3
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003712 propranolol Drugs 0.000 claims description 3
- 229960002370 sotalol Drugs 0.000 claims description 3
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- -1 isopropyl ester Chemical class 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 229960001416 pilocarpine Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 229960003933 dorzolamide Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940069275 cosopt Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960004834 levobunolol hydrochloride Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24812300P | 2000-11-13 | 2000-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200303771B true ZA200303771B (en) | 2004-05-17 |
Family
ID=22937766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200303771A ZA200303771B (en) | 2000-11-13 | 2003-05-15 | Improved treatment. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030018079A1 (fr) |
| EP (1) | EP1333837A1 (fr) |
| JP (1) | JP2004513148A (fr) |
| KR (1) | KR20030068150A (fr) |
| CN (1) | CN1233324C (fr) |
| AR (1) | AR035541A1 (fr) |
| AU (1) | AU2002215277A1 (fr) |
| BR (1) | BR0115208A (fr) |
| CA (1) | CA2426049A1 (fr) |
| EA (1) | EA200300560A1 (fr) |
| HU (1) | HUP0400548A3 (fr) |
| MX (1) | MXPA03004183A (fr) |
| NO (1) | NO20032122L (fr) |
| NZ (1) | NZ525817A (fr) |
| PL (1) | PL362855A1 (fr) |
| WO (1) | WO2002038158A1 (fr) |
| ZA (1) | ZA200303771B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| DK2261369T3 (da) * | 2002-03-13 | 2014-07-28 | Genomic Health Inc | Genekspressionsprofilering i biopsier af tumorvæv |
| US20060264353A1 (en) * | 2002-03-21 | 2006-11-23 | Maxey Kirk M | Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension |
| CA2496797C (fr) | 2002-08-29 | 2012-01-10 | Santen Pharmaceutical Co., Ltd. | Agent therapeutique contre le glaucome a base d'inhibiteurs de rho kinase et de prostaglandines |
| US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| ES2444841T3 (es) * | 2002-11-18 | 2014-02-27 | Santen Pharmaceutical Co., Ltd. | Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante |
| CA2536874A1 (fr) * | 2003-09-05 | 2005-03-17 | Novartis Ag | Compositions contenant des derives de benzo(g)quinoline et des derives de prostaglandine |
| MXPA06007678A (es) | 2004-01-05 | 2006-09-01 | Nicox Sa | Nitroxiderivados de prostaglandinas. |
| DE602004018990D1 (de) * | 2004-05-26 | 2009-02-26 | Bayardo Arturo Jimenez | Verfahren zur herstellung einer latanoprost-augenlösung und so hergestellte lösung |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| US8629161B2 (en) | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
| PL1905452T3 (pl) | 2005-07-12 | 2013-11-29 | Kowa Co | Środek do zapobiegania lub leczenia jaskry |
| ITRM20080182A1 (it) | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| WO2010119305A1 (fr) * | 2009-04-14 | 2010-10-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Utilisation de composés ammonium quartenaire dans la dissolution du latanoprost |
| CN102085175B (zh) * | 2009-12-02 | 2013-01-30 | 沈阳兴齐眼药股份有限公司 | 一种眼用凝胶剂及其制备方法 |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| CA2860453C (fr) * | 2011-01-24 | 2020-04-28 | Inceptum Research & Therapeutics, Inc. | Compositions comprenant une prostaglandine pour le traitement de pathologies neuropsychiatriques |
| EP2671586B1 (fr) | 2011-02-04 | 2018-05-30 | Kowa Co., Ltd. | Pharmacothérapie pour la prévention ou le traitement du glaucome |
| CN102389433A (zh) * | 2011-11-04 | 2012-03-28 | 兆科药业(香港)有限公司 | 一种药物组合物及其复方制剂 |
| EP3730138B1 (fr) | 2017-12-21 | 2024-02-14 | Santen Pharmaceutical Co., Ltd. | Combinaison de sepetaprost et de ripasudil pour l'utilisation dans la prophylaxie ou le traitement du glaucome ou de l'hypertension oculaire |
| WO2019124487A1 (fr) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | Association de l'omidénépag |
-
2001
- 2001-11-09 AR ARP010105259A patent/AR035541A1/es not_active Application Discontinuation
- 2001-11-09 US US10/035,963 patent/US20030018079A1/en not_active Abandoned
- 2001-11-12 PL PL01362855A patent/PL362855A1/xx unknown
- 2001-11-12 HU HU0400548A patent/HUP0400548A3/hu unknown
- 2001-11-12 EP EP01983882A patent/EP1333837A1/fr not_active Withdrawn
- 2001-11-12 JP JP2002540741A patent/JP2004513148A/ja not_active Withdrawn
- 2001-11-12 KR KR10-2003-7006437A patent/KR20030068150A/ko not_active Withdrawn
- 2001-11-12 WO PCT/SE2001/002499 patent/WO2002038158A1/fr not_active Ceased
- 2001-11-12 AU AU2002215277A patent/AU2002215277A1/en not_active Abandoned
- 2001-11-12 MX MXPA03004183A patent/MXPA03004183A/es unknown
- 2001-11-12 BR BR0115208-4A patent/BR0115208A/pt not_active IP Right Cessation
- 2001-11-12 CA CA002426049A patent/CA2426049A1/fr not_active Abandoned
- 2001-11-12 CN CNB018185924A patent/CN1233324C/zh not_active Expired - Fee Related
- 2001-11-12 EA EA200300560A patent/EA200300560A1/ru unknown
- 2001-11-12 NZ NZ525817A patent/NZ525817A/en unknown
-
2003
- 2003-05-12 NO NO20032122A patent/NO20032122L/no unknown
- 2003-05-15 ZA ZA200303771A patent/ZA200303771B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004513148A (ja) | 2004-04-30 |
| NO20032122D0 (no) | 2003-05-12 |
| CA2426049A1 (fr) | 2002-05-16 |
| AR035541A1 (es) | 2004-06-16 |
| WO2002038158A1 (fr) | 2002-05-16 |
| WO2002038158A8 (fr) | 2003-01-30 |
| AU2002215277A1 (en) | 2002-05-21 |
| MXPA03004183A (es) | 2004-12-02 |
| BR0115208A (pt) | 2003-10-07 |
| CN1233324C (zh) | 2005-12-28 |
| CN1473046A (zh) | 2004-02-04 |
| EA200300560A1 (ru) | 2003-10-30 |
| PL362855A1 (en) | 2004-11-02 |
| EP1333837A1 (fr) | 2003-08-13 |
| US20030018079A1 (en) | 2003-01-23 |
| HUP0400548A3 (en) | 2007-05-29 |
| KR20030068150A (ko) | 2003-08-19 |
| NZ525817A (en) | 2005-03-24 |
| NO20032122L (no) | 2003-07-01 |
| HUP0400548A2 (hu) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200303771B (en) | Improved treatment. | |
| JP4934653B2 (ja) | Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
| US12161629B2 (en) | Methods and compositions for treatment of glaucoma and related conditions | |
| JP2019142977A (ja) | 緑内障予防又は治療のための薬物療法 | |
| JP2009298808A (ja) | Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
| US20040213782A1 (en) | Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure | |
| JP7630944B2 (ja) | ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物 | |
| JP4482726B2 (ja) | Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
| EP3431074A1 (fr) | Solutions bimatoprost et timolol sans conservateur | |
| JP2009102290A (ja) | 高眼圧症の治療のための医薬組成物 | |
| Sit et al. | Effects of medications and surgery on intraocular pressure fluctuation | |
| Lindén | Therapeutic potential of prostaglandin analogues in glaucoma | |
| Diestelhorst et al. | The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study | |
| Shin et al. | The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy | |
| JP2012250951A (ja) | アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤 | |
| US20240216334A1 (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocularconditions | |
| Erdoǧan et al. | A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2% | |
| HK1059041A (en) | Improved treatment | |
| El-Saied et al. | Evaluation of topical monotherapy for early primary open angle glaucoma patient | |
| Aihara et al. | Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy | |
| CA3115815C (fr) | Methodes et compositions permettant le traitement du glaucome et d'affections apparentees | |
| JP2025067992A (ja) | ブリモニジンを含む、患者における眼圧を下降させるための組成物 | |
| JP2024506872A (ja) | Ｅｐ２受容体アゴニストの眼窩周囲投与のための組成物および方法 | |
| Mandić et al. | Suvremeno liječenje glaukoma otvorenog kuta | |
| Mandić et al. | Current management of open angle glaucoma |